Kymera Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule medicines through targeted protein degradation, a modality that leverages the body's natural protein recycling system to eliminate disease-causing proteins that traditional drugs cannot effectively address. The company focuses primarily on immunology and inflammatory diseases where substantial unmet needs exist, targeting oral alternatives to injectable biologics that offer improved patient convenience and lower manufacturing costs. Kymera monetizes through strategic collaborations, including agreements with Sanofi and Gilead that provide upfront payments, development and commercial milestone payments, and royalties on eventual product sales, while maintaining a proprietary patent portfolio covering its core degradation technology.